{"id":"https://genegraph.clinicalgenome.org/r/efa87746-c256-4780-a46a-917fe442ad8fv1.0","type":"EvidenceStrengthAssertion","dc:description":"RNASEH2B-related Type 1 Interferonopathy, Autosomal Recessive\n\nRNASEH2B was first reported in relation to autosomal recessive Aicardi-Goutieres syndrome type 2 (OMIM: 610326) in 2006 (PMID: 16845400). RNASEH2B encodes the ribonuclease H2 subunit B, which comprises 308 amino acids. RNASEH enzymes endolytically cleave ribonucleotides from RNA:DNA duplexes, which occur during DNA replication, transcription and translation. RNASEH2 has been proposed to function in the removal of lagging strand Okazaki fragment RNA primers during DNA replication, as well as in the excision of single ribonucleotides from RNA:DNA duplexes (PMIDs: 21177854, 16845400). \n\nThe described autosomal recessive RNASEH2B phenotype is considered to be a form of type 1 interferonopathy, which is defined as a condition in which increased type 1 interferon signaling leads to autoimmune and neurological disorders (MONDO: 0700257). These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response. Individuals with biallelic variants in RNASEH2B can present with a range of symptoms of variable severity and age of onset, within the context of an autoimmune disease.\n\nAt least 10 unique variants (missense, splicing, nonsense) have been reported across 13 probands in 6 publications (PMIDs: 33981319,  33307271, 36775013, 22882256, 39183359, 25604658) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity is thought to be loss of function. This gene-disease relationship is also supported by experimental evidence (model system studies, PMIDs: 34655526, 26903602). A study by Aditi et al., 2021 generated a murine model of neural Rnaseh2b inactivation (Rnaseh2bNes-cre), which demonstrated cerebellar atrophy, loss of granule neurons and interneurons, thinning of the corpus callosum, loss of oligodendrocytes, and white matter abnormalities. A study by Mackenzie et al., 2016 generated a murine model by knock-in of the A174T missense variant (c.520A>G) into exon 7 of Rnaseh2b in mouse embryonic stem cells, which demonstrated reduced cellular levels of all three RNase H2 subunits and demonstrated significant interferon-stimulated gene (ISG) transcript upregulation that recapitulated the ISG signature observed in RNase H2 AGS patients. \n\nIn summary, there is definitive evidence supporting the relationship between RNASEH2B and autosomal recessive RNASEH2B-related type 1 interferonopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic setting, and has been upheld over time. This classification was approved by the ClinGen Leukodystrophy and Leukoencephalopathy GCEP on the meeting date November 20, 2024 (SOP Version 11). \n\n\n\n\n\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/efa87746-c256-4780-a46a-917fe442ad8f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2025-01-10T17:09:16.656Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2025-01-10T18:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc9cd6de-88c7-4345-8b15-24b1f6c048e3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8982ac2-2be2-4b45-aadc-7c5182144fee","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8982ac2-2be2-4b45-aadc-7c5182144fee_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RT-PCR analysis of cDNA from patient fibroblasts showed predominantly skipping of exon 5 (Fig. 1C,D), leading to an out-of-frame transcript.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a8982ac2-2be2-4b45-aadc-7c5182144fee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.322-3C>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6985544"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/bc9cd6de-88c7-4345-8b15-24b1f6c048e3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","rdfs:label":"Ostergaard_ patient 4","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"failure to thrive, decreased visual contact, developmental regression, feeding difficulty, decreased spontaneous movement, hypertonia, leukodystrophy on brain MRI, hypoplasia of corpus callosum, microcephaly","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a8982ac2-2be2-4b45-aadc-7c5182144fee_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/d250f90e-e2e9-4f8d-9dc2-ef7815032034_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6f9ec34-1d3a-45fa-ad85-ca33c02aa55e","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6f9ec34-1d3a-45fa-ad85-ca33c02aa55e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reijns et al., 2011 showed that A177T significantly destabilizes the Rnase H2 complex, as measured by a reduction in thermal stability of recombinant RNase H2.\nNishimura et al., 2019 also demonstrated a decrease in stability of the RNase H2 complex as assessed by thermal denaturation assay","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e6f9ec34-1d3a-45fa-ad85-ca33c02aa55e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.529G>A (p.Ala177Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA251724"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/d250f90e-e2e9-4f8d-9dc2-ef7815032034","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 4","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"clinical diagnosis of late-onset Aicardi Goutières syndrome by experts in the field, individual phenotype information not available ","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/e6f9ec34-1d3a-45fa-ad85-ca33c02aa55e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/22719a50-4b8a-4600-b010-bcc6cd2e86df_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14f124f5-1de3-4673-9374-34c5d62d52e3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14f124f5-1de3-4673-9374-34c5d62d52e3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Publication by Nishimura et al., 2019 (PMID: 31529068) and Reijns et al., 2011 (PMID: 21177854) both demonstrated decreased stability of the RNase H2 complex as measured by thermal denaturation assay.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/14f124f5-1de3-4673-9374-34c5d62d52e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9f51ed03-0578-4a4b-aa8d-e9fad982ee1e","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9f51ed03-0578-4a4b-aa8d-e9fad982ee1e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d3b3c777-3560-426b-8738-76f108633993","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.132T>A (p.Cys44Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6985446"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/22719a50-4b8a-4600-b010-bcc6cd2e86df","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/d3b3c777-3560-426b-8738-76f108633993"},{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"}],"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"clinical diagnosis of late-onset Aicardi Goutières syndrome by experts in the field, individual phenotype information not available ","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/14f124f5-1de3-4673-9374-34c5d62d52e3_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/9f51ed03-0578-4a4b-aa8d-e9fad982ee1e_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/04ba1ddb-2773-47c9-ae56-232e257df7f8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4ca487f-301e-43f0-89df-ed9ebce6d496","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4ca487f-301e-43f0-89df-ed9ebce6d496_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reijns et al., 2011 showed that A177T significantly destabilizes the RNase H2 complex, as measured by a reduction in thermal stability of recombinant RNase H2.\nNishimura et al., 2019 also demonstrated a decrease in stability of the RNase H2 complex as assessed by thermal denaturation assay","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e4ca487f-301e-43f0-89df-ed9ebce6d496_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36775013","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d9df5f5e-33b1-4be0-a6a9-cbffbb31762c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d9df5f5e-33b1-4be0-a6a9-cbffbb31762c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Leung et al., 2023 demonstrated that the c.322-17A>G variant created a new splice site, inserting a 16bp intronic sequence into the cDNA (Fig. 3). The insertion is expected to cause a premature stop codon (p.Gly108Leufs*12).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d9df5f5e-33b1-4be0-a6a9-cbffbb31762c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36775013","allele":{"id":"https://genegraph.clinicalgenome.org/r/6fda45cc-b716-4f25-8ec5-e05a527fb785","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.322-17A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA609910216"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/04ba1ddb-2773-47c9-ae56-232e257df7f8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36775013","rdfs:label":"Leung_proband 1","ageType":"AgeAtReport","ageUnit":"Months","ageValue":21,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/6fda45cc-b716-4f25-8ec5-e05a527fb785"},{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"}],"detectionMethod":"genome sequencing","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"abnormal gait, toe-walking, early developmental milestones met on time, developmental regression (stopped walking), hypertonia, abnormal MRI (increased T2 signal abnormality, subcortical and deep white matter), elevated neopterin (78 nmol/L)","previousTesting":true,"previousTestingDescription":"leukodystrophy next generation sequencing panel","secondTestingMethod":"Other","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/e4ca487f-301e-43f0-89df-ed9ebce6d496_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d9df5f5e-33b1-4be0-a6a9-cbffbb31762c_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a9f96be8-2f00-4e17-a153-17bb1e251678_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/891f607b-1d7a-4410-a78d-2dbdd37b61a7","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/891f607b-1d7a-4410-a78d-2dbdd37b61a7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Nishimura et al., 2019 (PMID: 31529068) demonstrated that V185G results in decreased stability of the RNase H2 complex. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/891f607b-1d7a-4410-a78d-2dbdd37b61a7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4b33513-55ed-4ef8-a3fe-86c63dd821e7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.554T>G (p.Val185Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA251728"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a9f96be8-2f00-4e17-a153-17bb1e251678","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 3","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4b33513-55ed-4ef8-a3fe-86c63dd821e7"},"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"clinical diagnosis of late-onset Aicardi Goutières syndrome by experts in the field, individual phenotype information not available","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/891f607b-1d7a-4410-a78d-2dbdd37b61a7_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7b5d41be-daf6-48ef-8cd2-46051bf4b8e7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/533b7c6d-df10-4a8f-a81e-3b94b58398e9","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/533b7c6d-df10-4a8f-a81e-3b94b58398e9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Authors demonstrated that variant results in deletion of first 30 residues of RNase H2B complex, which appears to strongly destabilize the complex as the region occurs within a beta-strand interfacing RNase H2B and RNase H2C. Variant was further proven to affect mRNA splicing in the Crow et al., 2016 publication (PMID: 25604658).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/533b7c6d-df10-4a8f-a81e-3b94b58398e9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39183359","allele":{"id":"https://genegraph.clinicalgenome.org/r/bac756bc-9e0f-4a14-ac2d-3a19197462ca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.65-13G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA609907940"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7b5d41be-daf6-48ef-8cd2-46051bf4b8e7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/39183359","rdfs:label":"Shibata_proband 1","ageType":"AgeAtOnset","ageUnit":"WeeksGestation","ageValue":38,"allele":{"id":"https://genegraph.clinicalgenome.org/r/bac756bc-9e0f-4a14-ac2d-3a19197462ca"},"detectionMethod":"1st tier: Hereditary autoimmune disease panel\n2nd tier: Whole genome sequencing","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Microcephaly, feeding difficulties, respiratory impairment, diarrhea, chilblain-like lesions, MRI revealed intracranial calcifications and polygyria. Generalized clonic seizures, dystonia, spasticity. Lack of head control.","previousTesting":false,"secondTestingMethod":"Genotyping","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/533b7c6d-df10-4a8f-a81e-3b94b58398e9_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/efba6d1d-ee67-44a6-aadd-25288d4b4e74_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15c5f5fc-50be-4649-8263-a4f47c535902","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15c5f5fc-50be-4649-8263-a4f47c535902_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reijns et al., 2011 showed that A177T significantly destabilizes the Rnase H2 complex, as measured by a reduction in thermal stability of recombinant RNase H2.\nNishimura et al., 2019 also demonstrated a decrease in stability of the RNase H2 complex as assessed by thermal denaturation assay","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/15c5f5fc-50be-4649-8263-a4f47c535902_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/efba6d1d-ee67-44a6-aadd-25288d4b4e74","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 6","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"clinical diagnosis of late-onset Aicardi Goutières syndrome by experts in the field, individual phenotype information not available ","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/15c5f5fc-50be-4649-8263-a4f47c535902_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/8518a5f4-103e-4c26-a9da-8c69ea5ebd9f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d0328e7-5d9f-45e2-8db3-3c32e8820b74","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d0328e7-5d9f-45e2-8db3-3c32e8820b74_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Authors demonstrated that variant results in deletion of first 30 residues of RNase H2B complex, which appears to strongly destabilize the complex as the region occurs within a beta-strand interfacing RNase H2B and RNase H2C. Variant was further proven to affect mRNA splicing in the Crow et al, 2016 publication (PMID: 25604658).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3d0328e7-5d9f-45e2-8db3-3c32e8820b74_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33981319","allele":{"id":"https://genegraph.clinicalgenome.org/r/bac756bc-9e0f-4a14-ac2d-3a19197462ca"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/38b362b8-3d26-4ce5-9542-762ea48aafec","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38b362b8-3d26-4ce5-9542-762ea48aafec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33981319","allele":{"id":"https://genegraph.clinicalgenome.org/r/201e2a9b-a1c0-4b4b-a419-d77e2734bb0b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.253C>G (p.Leu85Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA388258935"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8518a5f4-103e-4c26-a9da-8c69ea5ebd9f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33981319","rdfs:label":"Garau_proband 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/bac756bc-9e0f-4a14-ac2d-3a19197462ca"},{"id":"https://genegraph.clinicalgenome.org/r/201e2a9b-a1c0-4b4b-a419-d77e2734bb0b"}],"detectionMethod":"next generation sequencing (NGS) (number of genes not specified)","firstTestingMethod":"Other","phenotypeFreeText":"-Irritability\n-Sterile pyrexia\n-Neuromotor regression with loss of trunk and head control\n-Exaggerated startle reaction\n-Acquired microcephaly\n-Pyramidal and extrapyramidal features\n-Brain MRI: white matter hyperintensity involving periventricular and deep regions and slight cerebral atrophy.\n-LP showed pleocytosis\n-Interferon alpha levels (CSF): normal\n-Blood interferon signature: 6.862 (normal range: 0-2.22)","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/38b362b8-3d26-4ce5-9542-762ea48aafec_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/3d0328e7-5d9f-45e2-8db3-3c32e8820b74_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/41ead787-5129-4b91-aec6-898dd4fad6f2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1270b10e-bccc-440b-8aa8-bbd4121beb2d","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1270b10e-bccc-440b-8aa8-bbd4121beb2d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Publication by Nishimura et al., 2019 (PMID: 31529068) and Reijns et al., 2011 (PMID: 21177854) both demonstrated decreased stability of the RNase H2 complex as measured by thermal denaturation assay.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1270b10e-bccc-440b-8aa8-bbd4121beb2d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/41ead787-5129-4b91-aec6-898dd4fad6f2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Clinical diagnosis of late-onset Aicardi-Goutières syndrome by experts in the field. Individual phenotype information not available ","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/1270b10e-bccc-440b-8aa8-bbd4121beb2d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/73f3f393-7157-4c51-b4b8-a625325c76ac_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b56748dd-3e88-456a-9945-97b3b7973cbf","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b56748dd-3e88-456a-9945-97b3b7973cbf_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RT-PCR analysis of cDNA from patient fibroblasts showed predominantly skipping of exon 5 (Fig. 1C,D), leading to an out-of-frame transcript.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b56748dd-3e88-456a-9945-97b3b7973cbf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/73f3f393-7157-4c51-b4b8-a625325c76ac","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","rdfs:label":"Ostergaard_ patient 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad"},"firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"IUGR, microcephaly, eating difficulties, no expressive language, spasticity, chilblains, periventricular calcifications (CT), severe atrophy with hypoplasia of the corpus callosum, dysmyelination","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b56748dd-3e88-456a-9945-97b3b7973cbf_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/b4fc2317-b8c4-4075-ad35-ded35452ffa5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53516bc4-b133-4f77-abd0-56514ebdb0cd","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53516bc4-b133-4f77-abd0-56514ebdb0cd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25604658","allele":{"id":"https://genegraph.clinicalgenome.org/r/552d92ff-e397-4df9-9bf3-b28fb6e17698","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.485A>C (p.Lys162Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249998006"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/b4fc2317-b8c4-4075-ad35-ded35452ffa5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25604658","rdfs:label":"Crow_proband 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/552d92ff-e397-4df9-9bf3-b28fb6e17698"},"phenotypeFreeText":"met clinical diagnostic criteria for AGS based on review by a specialist (physician, expert in the field), individual phenotype information not available","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/53516bc4-b133-4f77-abd0-56514ebdb0cd_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/d394a01d-027b-418d-9ec2-9640c7f0ebda_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33a51695-f444-434f-9755-5873388ec8f5","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33a51695-f444-434f-9755-5873388ec8f5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RT-PCR analysis of cDNA from patient fibroblasts showed predominantly skipping of exon 5 (Fig. 1C,D), leading to an out-of-frame transcript.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/33a51695-f444-434f-9755-5873388ec8f5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/d394a01d-027b-418d-9ec2-9640c7f0ebda","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22882256","rdfs:label":"Ostergaard_ patient 3","allele":{"id":"https://genegraph.clinicalgenome.org/r/296c0a3c-0129-4cf6-8930-c246edb6a9ad"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"lack of eye contact, hypotonia, irritability, nystagmus, multiple periventricular calcifications (in the basal ganglia, central pons, medulla oblongata  and  cerebellum), cerebral  atrophy, microcephaly, elevated neopterin 2008 nmol/L (ref. 12–30 nmol/L)","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/33a51695-f444-434f-9755-5873388ec8f5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/d25ff84f-13b8-4371-ad4a-cc09e58f0c2c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1832d46b-5fc7-4180-85e6-d3e00aef83b4","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1832d46b-5fc7-4180-85e6-d3e00aef83b4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/a53835de-8bce-413a-a1e8-ec459f1d9039","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024570.4(RNASEH2B):c.510+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249998008"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/982fbb8d-94ca-4032-9ea4-a1ed44966dce","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/982fbb8d-94ca-4032-9ea4-a1ed44966dce_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reijns et al., 2011 showed that A177T significantly destabilizes the Rnase H2 complex, as measured by a reduction in thermal stability of recombinant RNase H2.\nNishimura et al., 2019 also demonstrated a decrease in stability of the RNase H2 complex as assessed by thermal denaturation assay","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/982fbb8d-94ca-4032-9ea4-a1ed44966dce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","allele":{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d25ff84f-13b8-4371-ad4a-cc09e58f0c2c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33307271","rdfs:label":"Piccoli_proband 7","allele":[{"id":"https://genegraph.clinicalgenome.org/r/d376dcda-83ce-4b67-932c-a8d948302629"},{"id":"https://genegraph.clinicalgenome.org/r/a53835de-8bce-413a-a1e8-ec459f1d9039"}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"clinical diagnosis of late-onset Aicardi Goutières syndrome by experts in the field, individual phenotype information not available ","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1832d46b-5fc7-4180-85e6-d3e00aef83b4_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/982fbb8d-94ca-4032-9ea4-a1ed44966dce_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf20855e-de5b-4298-b709-bce27fdfd75b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3678597-c0a6-4f36-aa7e-dd0f343bafa4","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a17bb204-7519-4ccd-8414-e0575dc3a94c","type":"Finding","dc:description":"Demonstrated partial recapitulation of neuropathology seen in AGS. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34655526","rdfs:label":"Rnaseh2bNes-cre mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f25bbdfc-668f-494d-8396-329cc4683ff4","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ca0ef0f-94ac-4ca5-9d0f-819ecb2d8d96","type":"Finding","dc:description":"Demonstrated that abnormal RNase H2 deficiency leads to a proinflammatory response which is dependent upon the cGAS/STING pathway. This resulted in ISG transcriptional response and induction of proinflammatory cytokines, consistent with cell-intrinsic innate\nimmune activation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26903602","rdfs:label":"Rnaseh2b(A174T/A174T)knock-in mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b79508f6-9e65-4b54-9461-5454c78ad491","type":"EvidenceLine","dc:description":"Opted to not included as it primarily demonstrated embryonic lethality, enzyme reduction, and DNA damage. Will include Mackenzie et al., 2016 publication instead. ","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7b37012-bc42-42a1-bc22-11244b3e5005","type":"Finding","dc:description":"Demonstrated damaging impact of RNase H2 deficiency leading to low levels of enzyme activity, spontaneous DNA damage response, and increased genomic ribonucleotide load. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22802351","rdfs:label":"RNaseh2bKOF/KOF murine model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":9783,"specifiedBy":"GeneValidityCriteria11","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/g6nJGqYG-S4","type":"GeneValidityProposition","disease":"obo:MONDO_0700257","gene":"hgnc:25671","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_bf20855e-de5b-4298-b709-bce27fdfd75b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}